{"preliminary_commentary":{"by_channel":{"x_thread":2,"youtube":1},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":false},"commentary_summary":null,"drugs_tested":[["belrestotug","dostarlimab"]],"indication":"previously untreated PD-L1 high non-small-cell lung cancer","name":"GALAXIES Lung-301","nct_id":"NCT06472076","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=galaxies-lung-301-nct06472076. The price is an estimate of verified statements from the commentary indexed so far. Final coverage is set when the report is built. You never pay more than quoted: if the report is delivered at a smaller size, you pay that size's price, and anything paid above it is refunded. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_rule":"Never more than quoted: the buyer pays the smaller of price_usd and the price the delivered edition is sold at.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":null,"arms":[{"description":null,"label":"Dostarlimab plus belrestotug","type":"EXPERIMENTAL"},{"description":null,"label":"Pembrolizumab plus placebo","type":"ACTIVE_COMPARATOR"}],"collaborators":["iTeos Therapeutics"],"completion_date":{"date":"2027-08-30","type":"ESTIMATED"},"conditions":["Lung Cancer, Non-Small Cell"],"enrollment":{"count":88,"type":"ACTUAL"},"has_results":false,"interventions":[{"name":"Dostarlimab","otherNames":[],"type":"BIOLOGICAL"},{"name":"Belrestotug","otherNames":[],"type":"BIOLOGICAL"},{"name":"Pembrolizumab","otherNames":[],"type":"BIOLOGICAL"},{"name":"Placebo","otherNames":[],"type":"DRUG"}],"last_update":"2026-07-21","lead_sponsor":"GlaxoSmithKline","official_title":"A Randomized, Multicenter, Double-blind, Phase 3 Study to Investigate the Safety and Efficacy of Belrestotug in Combination With Dostarlimab Compared With Placebo in Combination With Pembrolizumab in Participants With Previously Untreated, Unresectable, Locally Advanced or Metastatic PD-L1 Selected Non-small Cell Lung Cancer (GALAXIES Lung-301)","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE3"],"primary_completion_date":{"date":"2026-06-30","type":"ACTUAL"},"primary_outcomes":[{"measure":"Number of Participants with Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)","timeFrame":"Up to approximately 138 weeks"},{"measure":"Number of Participants with TEAEs or SAEs leading to dose withdrawals or treatment discontinuation","timeFrame":"Up to approximately 138 weeks"}],"references":[],"start_date":{"date":"2024-06-10","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"A Study of Belrestotug Plus Dostarlimab Compared With Placebo Plus Pembrolizumab in Previously Untreated Participants With Programmed Death Ligand 1 (PD-L1) High Non-small-cell Lung Cancer (NSCLC)","url":"https://clinicaltrials.gov/study/NCT06472076"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.3","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/galaxies-lung-301-nct06472076"}